Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$14.1B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.34B |
| 3 |
Visa
V
|
+$714M |
| 4 |
VanEck Semiconductor ETF
SMH
|
+$638M |
| 5 |
HONA
Honeywell Aerospace
HONA
|
+$508M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.58B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$1.74B |
| 3 |
Apple
AAPL
|
+$1.66B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.3B |
| 5 |
Amazon
AMZN
|
+$1.23B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.34% |
| 2 | Technology | 17.88% |
| 3 | Financials | 5.92% |
| 4 | Consumer Discretionary | 4.3% |
| 5 | Communication Services | 3.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3351
Arteris
AIP
$1.17B
| $358K | ﹤0.01% |
7,368
-3,812
| -34% | -$122K |
|
3352
Voyager Therapeutics
VYGR
$165M
| $358K | ﹤0.01% |
102,204
+2,113
| +2% | +$8.01K |
|
3353
Verastem
VSTM
$701M
| $357K | ﹤0.01% |
93,408
+3,108
| +3% | +$15K |
|
3354
Caledonia Mining Corp
CMCL
$461M
| $356K | ﹤0.01% |
18,656
-25,430
| -58% | -$577K |
|
3355
Relmada Therapeutics
RLMD
$409M
| $355K | ﹤0.01% |
51,234
-37,719
| -42% | -$264K |
|
3356
Clover Health Investments
CLOV
$2.38B
| $355K | ﹤0.01% |
67,658
-10,376
| -13% | -$35.2K |
|
3357
Invesco DB Commodity Index Tracking Fund
DBC
$1.93B
| $354K | ﹤0.01% |
13,268
-1,171
| -8% | -$34.5K |
|
3358
Alto Neuroscience
ANRO
$1.04B
| $351K | ﹤0.01% |
13,318
-11,718
| -47% | -$271K |
|
3359
iShares Global Consumer Staples ETF
KXI
$1.12B
| $351K | ﹤0.01% |
5,200
| – | – |
|
|
CLYM
3360
Climb Bio
CLYM
$670M
| $351K | ﹤0.01% |
26,924
-22,012
| -45% | -$227K |
|
3361
Codexis
CDXS
$145M
| $351K | ﹤0.01% |
155,274
+181
| +0.1% | +$451 |
|
3362
Southside Bancshares
SBSI
$927M
| $350K | ﹤0.01% |
9,958
-1,901
| -16% | -$63K |
|
|
BBUC
3363
Brookfield Business Corp Class A Subordinate Voting Shares
BBUC
$5.23B
| $350K | ﹤0.01% |
11,738
-40,732
| -78% | -$1.35M |
|
3364
CALL
Berkshire Hathaway Class B
BRK.B
$1.08T
| $350K | ﹤0.01% |
700
-9,300
| -93% | -$4.47M |
|
3365
SGHC Ltd
SGHC
$6.08B
| $350K | ﹤0.01% |
25,799
-25,314
| -50% | -$321K |
|
3366
Red Violet
RDVT
$1.26B
| $348K | ﹤0.01% |
5,463
-649
| -11% | -$30.7K |
|
3367
C4 Therapeutics
CCCC
$367M
| $348K | ﹤0.01% |
74,516
-243,361
| -77% | -$832K |
|
3368
Genie Energy
GNE
$419M
| $347K | ﹤0.01% |
24,042
-694
| -3% | -$9.71K |
|
3369
Kura Sushi USA
KRUS
$473M
| $347K | ﹤0.01% |
6,028
+4,743
| +369% | +$260K |
|
|
OCTV
3370
Octave Intelligence
OCTV
$5.05B
| $347K | ﹤0.01% |
+21,282
| New | +$391K |
|
3371
inTEST
INTT
$148M
| $346K | ﹤0.01% |
19,052
+4,543
| +31% | +$76.9K |
|
3372
Paymentus
PAY
$3.8B
| $345K | ﹤0.01% |
14,278
-25,737
| -64% | -$632K |
|
3373
Superior Group of Companies
SGC
$205M
| $345K | ﹤0.01% |
26,291
-902
| -3% | -$10.8K |
|
3374
Nelnet
NNI
$4.45B
| $345K | ﹤0.01% |
2,587
-11,708
| -82% | -$1.55M |
|
3375
AnaptysBio
ANAB
$1.52B
| $345K | ﹤0.01% |
5,107
-2,333
| -31% | -$141K |
|
Similar funds
Barclays's Q2 2026 Portfolio in Review
As of Q2 2026, Barclays held 5,723 positions worth $521B, up 25% from $416B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2026 filing shows 722 new, 1,729 increased, 2,511 reduced and 392 closed positions. Its largest new stake was Honeywell Aerospace: 2,302,561 shares worth $509M. The largest sale was NVIDIA, an estimated $4.58B.
By sector, the portfolio is most concentrated in Miscellaneous at 55% of assets, up from 46% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2026 buy was Honeywell Aerospace: 2,302,561 shares worth $509M.
- Barclays added most to iShares MSCI Emerging Markets ETF in Q2 2026, an estimated $14.1B increase.
- Barclays's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $4.58B.
- Barclays fully exited Masimo in Q2 2026, selling an estimated $488M.
- Barclays's ten largest holdings make up 43% of its $521B portfolio in Q2 2026.
- Barclays opened 722 new positions and closed 392 in Q2 2026.
- Barclays's portfolio value rose 25% quarter-over-quarter to $521B.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.